LimmaTech Biologics AG
Quick facts
Marketed products
- MenACWY · Immunology / Infectious Disease
MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y.
Phase 2 pipeline
- Flexyn2a · Oncology
Flexyn2a is a monoclonal antibody that targets the PD-1 receptor. - Shigella4V2
Phase 1 pipeline
- Bioconjugate pneumococcal vaccine
- Flexyn2a plus adjuvant
- Kleb4V low dose
- Kleb4V target dose
- LTB-SA7
- Multivalent plain polysaccharide vaccine
- Shigella 4V
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: